ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER4344550FOR434455FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER50896110FOR5089611FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER508961102 YEARS5089611AGAINST MARKER THERAPEUTICS INC57055L206US57055L206005/01/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER2110850FOR211085FOR MARKER THERAPEUTICS, INC.57055L206US57055L206005/01/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1142850FOR114285FOR VERONA PHARMA PLC925050106US925050106409/24/2025To approve, on an advisory, non-binding basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the Transaction, as disclosed in the table entitled "Potential Payments to Named Executive Officers" beginning on page 70 of the proxy statement, including the associated narrative discussion, and the agreements or understandings pursuant to which such compensation may be paid or become payable.SECTION 14A SAY-ON-PAY VOTESISSUER6153520FOR615352FOR COMPASS PATHWAYS PLC20451W101US20451W101805/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2025SECTION 14A SAY-ON-PAY VOTESISSUER14323360FOR1432336FOR SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER770310FOR77031FOR SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER13168060FOR1316806FOR UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER1080000FOR108000FOR